SOPHIA GENETICS SA

Investor insights on SOPHiA GENETICS insider sales amid market volatility—understand how portfolio moves and pipeline progress shape the future of cloud‑genomics.

Valente Manuela’s $3.20 insider buy of 10k SOPHiA GENETICS shares amid a strong rally signals confidence in the AI‑powered genomic analytics firm’s undervalued future.

Inside SOPHiA GENETICS’ latest trades reveal disciplined buying, mixed leadership confidence, and growth tied to evolving genomic reimbursement models.

Insider sales at SOPHiA GENETICS continue to pace momentum—Xu Zhenyu sells 10K shares via Rule 10b5‑1, yet company’s AI‑driven precision medicine outlook remains bullish.

Analyze SOPHiA Genetics’ July insider trades and market context – discover how disciplined 10‑b‑5‑1 actions reflect investor confidence and future growth opportunities in genomic analytics.

Rule‑based insider sale by SOPHiA GENETICS’ chairman shows confidence, not panic, amid rising AI‑driven oncology demand and a 27% partner growth surge.

Insider sales at Sophia Genetics reveal a disciplined liquidity plan, not a warning sign—watch the SaaS shift and Q3 earnings for next‑step valuation clues.

Insightful insider sale by SOPHiA GENETICS CFO Car­do­za George shows strategic equity management, not a warning sign, amid a $57 m public offering and cloud‑AI expansion.

Insider selling by SOPHiA GENETICS’s chief scientist shows steady divestiture, modest market impact, and mixed executive sentiment—watch for dilution and confidence signals.

CEO Camblong Jurgi sells 8,500 shares at $5.24, just before SOPHiA’s AGM and a July CEO transition—yet the company’s AI‑driven health‑care platform, strong fundamentals, and regulatory approvals promise continued value.